These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 11483779)

  • 21. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.
    Singh DK; Liu Z; Sheffer D; Mackay GA; Smith M; Dhillon S; Hegde R; Jia F; Adany I; Narayan O
    J Virol; 2005 Mar; 79(6):3419-28. PubMed ID: 15731236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.
    Davis D; Koornstra W; Fagrouch Z; Verschoor EJ; Heeney JL; Bogers WM
    PLoS One; 2013; 8(8):e72702. PubMed ID: 23977339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    Mascola JR; Lewis MG; Stiegler G; Harris D; VanCott TC; Hayes D; Louder MK; Brown CR; Sapan CV; Frankel SS; Lu Y; Robb ML; Katinger H; Birx DL
    J Virol; 1999 May; 73(5):4009-18. PubMed ID: 10196297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM
    Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying
    Scinto HB; Gupta S; Thorat S; Mukhtar MM; Griffiths A; Delgado J; Plake E; Vyas HK; Strickland A; Byrareddy SN; Montefiori DC; LaBranche C; Pal R; Treece J; Orndorff S; Ferrari MG; Weiss D; Chenine AL; McLinden R; Michael N; Kim JH; Robb ML; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Ruprecht RM
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
    Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
    Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.
    Moog C; Dereuddre-Bosquet N; Teillaud JL; Biedma ME; Holl V; Van Ham G; Heyndrickx L; Van Dorsselaer A; Katinger D; Vcelar B; Zolla-Pazner S; Mangeot I; Kelly C; Shattock RJ; Le Grand R
    Mucosal Immunol; 2014 Jan; 7(1):46-56. PubMed ID: 23591718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge.
    Klein K; Veazey RS; Warrier R; Hraber P; Doyle-Meyers LA; Buffa V; Liao HX; Haynes BF; Shaw GM; Shattock RJ
    J Virol; 2013 Nov; 87(21):11604-16. PubMed ID: 23966410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
    Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
    Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
    EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.
    Mascola JR
    Vaccine; 2002 May; 20(15):1922-5. PubMed ID: 11983246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
    Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
    J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellulose acetate 1,2-benzenedicarboxylate protects against challenge with pathogenic X4 and R5 simian/human immunodeficiency virus.
    Boadi T; Schneider E; Chung S; Tsai L; Gettie A; Ratterree M; Blanchard J; Neurath AR; Cheng-Mayer C
    AIDS; 2005 Oct; 19(15):1587-94. PubMed ID: 16184027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.
    Jaworski JP; Kobie J; Brower Z; Malherbe DC; Landucci G; Sutton WF; Guo B; Reed JS; Leon EJ; Engelmann F; Zheng B; Legasse A; Park B; Dickerson M; Lewis AD; Colgin LM; Axthelm M; Messaoudi I; Sacha JB; Burton DR; Forthal DN; Hessell AJ; Haigwood NL
    J Virol; 2013 Oct; 87(19):10447-59. PubMed ID: 23885083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.
    Shingai M; Donau OK; Plishka RJ; Buckler-White A; Mascola JR; Nabel GJ; Nason MC; Montefiori D; Moldt B; Poignard P; Diskin R; Bjorkman PJ; Eckhaus MA; Klein F; Mouquet H; Cetrulo Lorenzi JC; Gazumyan A; Burton DR; Nussenzweig MC; Martin MA; Nishimura Y
    J Exp Med; 2014 Sep; 211(10):2061-74. PubMed ID: 25155019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.
    Moldt B; Le KM; Carnathan DG; Whitney JB; Schultz N; Lewis MG; Borducchi EN; Smith KM; Mackel JJ; Sweat SL; Hodges AP; Godzik A; Parren PW; Silvestri G; Barouch DH; Burton DR
    AIDS; 2016 Jun; 30(10):1543-51. PubMed ID: 27243773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.
    Hessell AJ; Poignard P; Hunter M; Hangartner L; Tehrani DM; Bleeker WK; Parren PW; Marx PA; Burton DR
    Nat Med; 2009 Aug; 15(8):951-4. PubMed ID: 19525965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.